Mold-Tek Packaging Ltd

- The company has committed capex of around INR 55 to 58 crores for various expansions in FY '25. - If volumes grow in pharma, additional growth investment might be required in the second half of the year. - Overall capex for FY '25 is expected to be around INR 75 to 80 crores, compared to INR 140 crores last year. - No direct mention or indication of new fundraising through debt or equity was made in the transcript. - Focus seems to be on utilizing internal accruals and existing resources for capacity expansion and ramp-up.

- Current committed capex for FY '25 is around INR 55 to 58 crores for various expansions. - Additional growth investment in pharma may raise total capex to INR 75 to 80 crores by year-end. - Capacity expansions include increasing ABG plants' capacity by 60% to 75% at Cheyyur and Mahad. - Mahad plant will start supply from September/October, adding to volume growth. - Pharma plant capacity may be enhanced with auxiliary machines within 3-4 months if needed. - Capex in FY '25 is lower than last year's INR 140 crores. - The company aims to double ABG capacities and expand pharmaceutical capacity to boost growth.

- Volume growth guidance for FY '25 is around 15%, with a higher run rate of 17% needed in the remaining 9 months due to a moderate Q1 growth of 7.5%. - Pharma segment is expected to grow significantly, contributing around INR15-20 crores in FY '25 with higher EBITDA, and potentially pushing turnover to INR50-60 crores by FY '26. - Qpacks are growing rapidly, with expectations of 40-50% volume growth in the Food & FMCG segment. - ABG segment capacity expansions (especially Cheyyar and Mahad plants) will add over 1,000 tons/month volume, supporting growth. - Paints sector growth is expected around 8-10%, driven by ABG and other clients. - Overall volumes grew by 7.5% in Q1 with a recent trend showing improvement, targeting continued growth from Q3 onward. - The company aims to reach INR1,000 crores top line and INR100 crores PAT by FY '26/'27 largely driven by pharma and ABG expansions.

- The company targets overall volume growth of around 15% for FY '25, with a high run rate needed in last 3 quarters. - Pharma segment expected to significantly contribute from Q3 FY '25, with turnover potential of INR50-60 crores by FY '26, and handsome EBITDA of INR100-150 per kg depending on product mix. - EBITDA per kg target is 40 by end of FY '25, up from 37.1 in Q1 FY '25, driven by pharma contribution and ramp-up in ABG capacities. - Capex for FY '25 is estimated at INR75-80 crores (vs INR140 crores last year) aimed at capacity expansion for ABG and pharma. - Revenue could approach INR1,000 crores in FY '25/'26, with PAT potentially crossing INR100 crores if pharma growth materializes well by FY '26/'27. - Increased capacity utilization expected from Q3 onwards in pharma and ABG plants will drive improved earnings.

- The company is witnessing strong indications for volume ramp-up, especially from pharma and ABG plants starting Q2 and Q3. - For pharma, orders are developing rapidly with 4 major clients auditing and approving the company as a vendor; several products are in final development stages. - Expected pharma sales: INR 80 lakhs in Q1, INR 2-2.5 crores in Q2, and INR 5-6 crores in Q3 and Q4, totaling INR 15-20 crores for the year. - ABG paints plant (including Mahad starting September/October) expected to add more than 1,000 tons per month in volumes. - Expansion efforts are ongoing with loading expected by December for new volumes, aiming to double capacity, particularly in North India. - Overall volume guidance remains mid-teens (around 15%) growth for FY '25, supported by pharma and ABG orderbooks. - Utilization at ABG plants currently around 40-45%, expected to reach 50-60% in the full year.